On the heels of raising $26 million in fresh capital, the company that manufactures an inhalable form of insulin has a new international distribution agreement in place.

MannKind Pharmaceuticals announced the new pact on Friday with Tanner Pharma Group, a Charlotte, N.C.-based company that distributes medications in more than 75 countries. The companies did not disclose immediately financial terms of the agreement.

MannKind is based in Westlake, Calif., and manufactures in Danbury a powdered form of insulin called Afrezza that can be inhaled to treat diabetes, a condition in which the pancreas produces too little insulin which helps cells absorb sugar for energy in the body. MannKind engineers developed Afrezza to begin taking effect in as little as 12 minutes.

Afrezza has been approved for use in the United States since February 2015, with MannKind sales totaling $3.5 million in the first quarter of 2018, up from $3 million a year earlier, a period in which it moved some office work to Westlake Village that had been performed in Danbury as it worked to improve efficiencies after a $30.4 million loss for the quarter. The company is slated to release its latest quarterly results next week.

In April, MannKind raised $26 million in fresh financing via a sale of stock, on the heels of $58 million it received last year.

In 2014, MannKind reached a license and supply agreement with Sanofi that awarded the French giant responsibility for global commercialization of Afrezza, but the deal was canceled, with MannKind assuming anew worldwide commercialization. By 2017, MannKind had developed its own sales force, while holding open the option of bringing in other companies to help sell Afrezza to endocrinologists and primary-care doctors.

This past May, MannKind offered an India company called Cipla a deal to distribute Afrezza in India, with MannKind receiving $2.2 million up front with possible additional royalties and payments if sales reach an unspecified level.

In May, MannKind won approval from Brazil regulators for the Afrezza inhaler’s use there.

“One of the challenges we’ve had since we got the product back from Sanofi is really planning for the long term, and with the capital raised last year and the recent capital raise, we’ve been able to continue to lay out our plan for the next 18 to 24 months,” said MannKind CEO Michael Castagna in May during a conference call with investment analysts. “The buildup of the scientific story is something that we believe has been missing on Afrezza.”

Alex.Soule@scni.com; 203-842-2545; @casoulman